Technologies do not affect everyone equally. This is one of the most persistent and uncomfortable truths running through Films from the Future. Across the book's twelve films, we see again and again how innovation can amplify existing inequalities, concentrate power in the hands of a few, and leave entire communities behind. The question is not just whether a technology works, but who it works for.
Elysium presents the starkest vision of this dynamic. In the film's near-future world, the wealthy have retreated to an orbital habitat where advanced medical technology can cure virtually any disease or injury in seconds. Meanwhile, the rest of humanity is left on an overcrowded, polluted Earth with minimal access to healthcare, decent work, or hope.
The book acknowledges that Elysium is a blunt instrument, an overly simplified portrayal of inequality. But it argues that the film's core insight is not far from reality. Technologies like bioprinting, which could one day produce replacement organs and tissues, have the potential to transform medicine. The question the film forces us to confront is whether those transformative benefits will be broadly shared or hoarded by those who can afford them. In a world where access to basic healthcare remains deeply unequal, the arrival of revolutionary medical technologies could just as easily widen that gap as close it.
Limitless explores a subtler but equally consequential form of inequality. The film's cognitive-enhancing drug NZT-48 does not just make its users smarter; it gives them an edge over everyone who does not have access to it. The book connects this to the real-world emergence of nootropics and smart drugs, noting that their use is already concentrated among those in competitive, high-status environments like Silicon Valley and elite universities.
The implications ripple outward. If cognitive enhancement becomes normalized, who will have access? Will it be available to the student working two jobs to pay tuition, or only to those who can afford boutique brain-hacking regimens? The book raises the possibility of a world where the cognitively enhanced pull further ahead while those without access fall further behind, not through any fault of their own, but because the playing field has been tilted by technology.
Ghost in the Shell takes these questions into the realm of human augmentation. Set in a future where cybernetic enhancement is widespread, the film explores a world where the boundary between human and machine has blurred. But augmentation is not equally available. The film hints at a society stratified by the degree to which people can afford to upgrade their bodies and minds.
The book draws this out into a broader discussion of what happens when the technologies that define human capability become products for sale. If augmentation can extend life, sharpen cognition, and enhance physical ability, then access to augmentation becomes access to a fundamentally different quality of existence. The gap is no longer just between rich and poor, but between the augmented and the unaugmented, a division that could become biological as well as economic.
Even Jurassic Park, a film more commonly associated with scientific hubris, contains a thread about power and access. John Hammond is a mega-entrepreneur whose wealth and influence allow him to pursue a technological vision that would be impossible for anyone without his resources. The scientists who raise concerns are ultimately subordinate to the man writing the checks. The book uses this to highlight a recurring pattern: when innovation is driven by wealthy individuals, their priorities, their blind spots, and their appetites for risk shape the direction technology takes.
This is not just a fictional concern. The book notes the growing influence of technology entrepreneurs who have the resources to pursue ambitious and potentially risky innovations with minimal oversight. When the direction of technology development is determined by a handful of individuals with extraordinary wealth, the priorities of everyone else can easily be sidelined.
Across these films, the book surfaces questions that resist easy answers:
The book does not suggest that technology is inherently a tool of oppression. It recognizes the extraordinary potential of innovations to improve lives across the board. But it insists that this potential will not be realized automatically. Without deliberate attention to questions of access and equity, the default trajectory of innovation is toward those who already have the most.
For the technologies that raise these access questions, see Smart Drugs and Cognitive Enhancement, Bioprinting, Human Augmentation, and Automation and the Future of Work. For how corporate incentives shape these dynamics, see Corporate Responsibility and the Profit Motive.